<!DOCTYPE article PUBLIC "-//NLM//DTD Journal Archiving and Interchange DTD v2.3 20070202//EN" "archivearticle.dtd"><article xmlns:xlink="http://www.w3.org/1999/xlink" article-type="research-article"><front><journal-meta><journal-id journal-id-type="nlm-ta">BMC Cancer</journal-id><journal-title>BMC Cancer</journal-title><issn pub-type="epub">1471-2407</issn><publisher><publisher-name>BioMed Central</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="publisher-id">1471-2407-8-100</article-id><article-id pub-id-type="pmid">18405391</article-id><article-id pub-id-type="doi">10.1186/1471-2407-8-100</article-id><article-categories><subj-group subj-group-type="heading"><subject>Research Article</subject></subj-group></article-categories><title-group><article-title>Expression of estrogen receptor beta in the breast carcinoma of BRCA1 mutation carriers</article-title></title-group><contrib-group><contrib id="A1" corresp="yes" contrib-type="author"><name><surname>Litwiniuk</surname><given-names>Maria M</given-names></name><xref ref-type="aff" rid="I1">1</xref><email>litwiniuk@skrzynka.pl</email></contrib><contrib id="A2" contrib-type="author"><name><surname>Ro&#x0017c;nowski</surname><given-names>Krzysztof</given-names></name><xref ref-type="aff" rid="I1">1</xref><email>krzysztof.roznowski@oncology.am.poznan.pl</email></contrib><contrib id="A3" contrib-type="author"><name><surname>Filas</surname><given-names>Violetta</given-names></name><xref ref-type="aff" rid="I1">1</xref><email>vfilas@wp.pl</email></contrib><contrib id="A4" contrib-type="author"><name><surname>Godlewski</surname><given-names>Dariusz D</given-names></name><xref ref-type="aff" rid="I2">2</xref><email>godlewski.open@wp.pl</email></contrib><contrib id="A5" contrib-type="author"><name><surname>Stawicka</surname><given-names>Ma&#x00142;gorzata</given-names></name><xref ref-type="aff" rid="I2">2</xref><email>gosiastawicka.open@wp.pl</email></contrib><contrib id="A6" contrib-type="author"><name><surname>Kaleta</surname><given-names>Remigiusz</given-names></name><xref ref-type="aff" rid="I3">3</xref><email>remigiusz.kaleta@pharmacia.com</email></contrib><contrib id="A7" contrib-type="author"><name><surname>Br&#x00119;borowicz</surname><given-names>Jan</given-names></name><xref ref-type="aff" rid="I1">1</xref><email>janbreborowicz@wp.pl</email></contrib></contrib-group><aff id="I1"><label>1</label>Clinic of Oncology, Poznan University of Medical Sciences, Poznan, Poland</aff><aff id="I2"><label>2</label>Prophylactics and Epidemiology Centre in Poznan, Poznan, Poland</aff><aff id="I3"><label>3</label>Private Oncological Practice, Gliwice, Poland</aff><pub-date pub-type="collection"><year>2008</year></pub-date><pub-date pub-type="epub"><day>13</day><month>4</month><year>2008</year></pub-date><volume>8</volume><fpage>100</fpage><lpage>100</lpage><ext-link ext-link-type="uri" xlink:href="http://www.biomedcentral.com/1471-2407/8/100"/><history><date date-type="received"><day>5</day><month>11</month><year>2007</year></date><date date-type="accepted"><day>13</day><month>4</month><year>2008</year></date></history><permissions><copyright-statement>Copyright &#x000a9; 2008 Litwiniuk et al; licensee BioMed Central Ltd.</copyright-statement><copyright-year>2008</copyright-year><copyright-holder>Litwiniuk et al; licensee BioMed Central Ltd.</copyright-holder><license license-type="open-access" xlink:href="http://creativecommons.org/licenses/by/2.0"><p>This is an Open Access article distributed under the terms of the Creative Commons Attribution License (<ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/2.0"/>), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.</p><!--<rdf xmlns="http://web.resource.org/cc/" xmlns:rdf="http://www.w3.org/1999/02/22-rdf-syntax-ns#" xmlns:dc="http://purl.org/dc/elements/1.1" xmlns:dcterms="http://purl.org/dc/terms"><Work xmlns:dc="http://purl.org/dc/elements/1.1/" xmlns:dcterms="http://purl.org/dc/terms/" rdf:about=""><license rdf:resource="http://creativecommons.org/licenses/by/2.0"/><dc:type rdf:resource="http://purl.org/dc/dcmitype/Text"/><dc:author> Litwiniuk M Maria litwiniuk@skrzynka.pl </dc:author><dc:title> Expression of estrogen receptor beta in the breast carcinoma of BRCA1 mutation carriers </dc:title><dc:date>2008</dc:date><dcterms:bibliographicCitation>BMC Cancer 8(1): 100-. (2008)</dcterms:bibliographicCitation><dc:identifier type="sici">1471-2407(2008)8:1&#x0003c;100&#x0003e;</dc:identifier><dcterms:isPartOf>urn:ISSN:1471-2407</dcterms:isPartOf><License rdf:about="http://creativecommons.org/licenses/by/2.0"><permits rdf:resource="http://web.resource.org/cc/Reproduction" xmlns=""/><permits rdf:resource="http://web.resource.org/cc/Distribution" xmlns=""/><requires rdf:resource="http://web.resource.org/cc/Notice" xmlns=""/><requires rdf:resource="http://web.resource.org/cc/Attribution" xmlns=""/><permits rdf:resource="http://web.resource.org/cc/DerivativeWorks" xmlns=""/></License></Work></rdf>--></license></permissions><abstract><sec><title>Background</title><p>Breast cancers (BC) in women carrying mutations in BRCA1 gene are more frequently estrogen receptor negative than the nonhereditary BC. Nevertheless, tamoxifen has been found to have a protective effect in preventing contralateral tumors in BRCA1 mutation carriers. The identification of the second human estrogen receptor, ER&#x003b2;, raised a question of its role in hereditary breast cancer. The aim of this study was to assess the frequency of ER&#x003b1;, ER&#x003b2;, PgR (progesterone receptor) and HER-2 expression in breast cancer patients with mutated <italic>BRCA1 </italic>gene and in the control group.</p></sec><sec sec-type="methods"><title>Methods</title><p>The study group consisted of 48 women with <italic>BRCA1 </italic>gene mutations confirmed by multiplex PCR assay. The patients were tested for three most common mutations of BRCA1 affecting the Polish population (5382insC, C61G, 4153delA). Immunostaining for ER&#x003b1;, ER&#x003b2; and PgR (progesterone receptor) was performed using monoclonal antibodies against ER&#x003b1;, PgR (DakoCytomation), and polyclonal antibody against ER&#x003b2; (Chemicon). The EnVision detection system was applied. The study population comprised a control group of 120 BC operated successively during the years 1998&#x02013;99.</p></sec><sec><title>Results</title><p>The results of our investigation showed that <italic>BRCA1 </italic>mutation carriers were more likely to have ER&#x003b1;-negative breast cancer than those in the control group. Only 14.5% of <italic>BRCA1</italic>-related cancers were ER&#x003b1;-positive compared with 57.5% in the control group (<italic>P </italic>&#x0003c; 0.0001). On the contrary, the expression of ER&#x003b2; protein was observed in 42% of <italic>BRCA1</italic>-related tumors and in 55% of the control group. An interesting finding was that most hereditary cancers (75% of the whole group) were triple-negative: ER&#x003b1;(-)/PgR(-)/HER-2(-) but almost half of this group (44.4%) showed the expression of ER&#x003b2;.</p></sec><sec><title>Conclusion</title><p>In the case of <italic>BRCA1</italic>-associated tumors the expression of ER&#x003b2; was significantly higher than the expression of ER&#x003b1;. This may explain the effectiveness of tamoxifen in preventing contralateral breast cancer development in <italic>BRCA1 </italic>mutation carriers.</p></sec></abstract></article-meta></front><body><sec><title>Background</title><p>In 1990 Hall et al. discovered that familial breast cancer is associated with a defect in one of the genes located in the 17q21 chromosome [<xref ref-type="bibr" rid="B1">1</xref>]. This finding began a new era of research into hereditary breast cancer and consequently led to the identification of the <italic>BRCA1 </italic>and <italic>BRCA2 </italic>suppressor genes in 1994 and 1995, respectively. Although the structures and localization of the <italic>BRCA1 </italic>and <italic>BRCA2 </italic>genes differ, their functions seem to be similar because their transcripts are involved in the same processes [<xref ref-type="bibr" rid="B2">2</xref>-<xref ref-type="bibr" rid="B6">6</xref>]. These genes are responsible for maintaining the proper course of the cell cycle, for the repair of DNA damage, and are also instrumental in the process of cell differentiation. <italic>BRCA1 </italic>is also partially responsible for the activity of estrogen receptors (ER) and, when mutated, can inhibit the functions of these receptors [<xref ref-type="bibr" rid="B7">7</xref>].</p><p><italic>BRCA1 </italic>and <italic>BRCA2 </italic>gene mutation carriers are at risk of developing breast cancer earlier than other patients. Breast cancer associated with this mutation has characteristic histopathological features: (i) the expression of estrogen and progesterone receptors is less frequently demonstrable, (ii) the grade of histopathological malignancy is higher and (iii) accumulation of p53 protein is observed more often than in sporadic cases of this malignancy [<xref ref-type="bibr" rid="B8">8</xref>,<xref ref-type="bibr" rid="B9">9</xref>]. Although these factors are usually associated with a poorer prognosis, their role in <italic>BRCA1 </italic>and <italic>BRCA2 </italic>mutation carriers is still controversial [<xref ref-type="bibr" rid="B10">10</xref>-<xref ref-type="bibr" rid="B15">15</xref>].</p><p>The role of tamoxifen in preventing the development of contralateral breast cancer in <italic>BRCA1 </italic>mutation carriers is not fully understood since it significantly reduces that risk despite low expression of ER [<xref ref-type="bibr" rid="B16">16</xref>]. The mechanism responsible for that has not been yet explained and estrogen receptor &#x003b2; may play a role here.</p><p>Estrogen receptor &#x003b2; (ER&#x003b2;) was discovered in 1996 and was given its name in order to differentiate it from the previously known type of estrogen receptor (now named estrogen receptor &#x003b1; &#x02013; ER&#x003b1;) [<xref ref-type="bibr" rid="B17">17</xref>,<xref ref-type="bibr" rid="B18">18</xref>]. The two estrogen receptors belong to a family of ligand-regulated transcription factors. They are transcripts of different genes sharing some structural similarities. When co-expressed, ER&#x003b1; and ER&#x003b2; may form homo- or heterodimers upon binding specific ligands. As dimers, ERs are able to start transcription activity in two ways: through direct binding to specific regions of DNA, or through protein-protein interaction with other transcription factors. In the case of co-expression of both ERs, their roles may overlap. In certain situations, however, ER&#x003b2; opposes the activity of ER&#x003b1; via the inhibition of ER&#x003b1;-mediated gene expression. These differences are also observed in the response to tamoxifen. This selective estrogen receptor modulator may work as a pure ER antagonist for ER&#x003b2;, while it may have a partially agonistic effect for ER&#x003b1; [<xref ref-type="bibr" rid="B19">19</xref>]. In spite of increasing knowledge regarding the structure and <italic>in vitro </italic>activity of ER&#x003b1; and ER&#x003b2;, their clinical role is still controversial and unclear [<xref ref-type="bibr" rid="B20">20</xref>].</p><p>For a better understanding of the functions of ER&#x003b2; we explored its expression in <italic>BRCA1 </italic>mutation carriers and looked for coexistence patterns with other hormonal receptors (ER&#x003b1;, PgR) and HER-2 receptor.</p></sec><sec sec-type="methods"><title>Methods</title><p>The study group included 48 patients with mutations in the <italic>BRCA1 </italic>gene. The control group consisted of 120 subsequent breast cancer cases diagnosed over the period of 1998&#x02013;1999. Patients from both groups underwent breast surgery from which specimens for histological and immunohistochemical testing were obtained. The study was approved by the local Bioethics Committee at the Medical University in Pozna&#x00144;.</p><p>Results of genetic tests were obtained from the Prophylactics and Epidemiology Center in Pozna&#x00144;. In the search for mutations in the <italic>BRCA1 </italic>gene, tests were performed on DNA isolated from peripheral blood lymphocytes using a commercially available kit. They were carried out for three most common mutations of <italic>BRCA1 </italic>gene affecting the Polish population (5382insC, C61G, 4153delA). In Poland those three mutations in BRCA1 account for 86% of all BRCA1 and BRCA2 mutations. In the search for 5382insC and 4153delA mutations, the ASA-PCR method was used. For the detection of C61G mutation, the RELP-PCR method was applied.</p><p>Histological and immunohistochemical tests were completed in the Department of Tumor Pathology of the Medical University in Pozna&#x00144;. From formalin fixed and paraffin embedded specimens, 4 &#x003bc;m sections were cut and mounted onto positively charged glass microscope slides (Superfrost Plus, Menzel-Glaser, Germany). The sections were deparaffinized, rehydrated and subjected to antigen retrieval in citrate buffer in a microwave oven. The slides were then incubated in 3% hydrogen peroxide for 10 minutes to block endogenous peroxidase activity.</p><p>The primary antibodies used for immunostaining were as follows:</p><p>1. for ER&#x003b1; &#x02013; a monoclonal mouse antibody clone 1D5 (Dako, Glostrup, Denmark; code No M 7047) was used at 1:50 dilution and slides were incubated at room temperature for 1 h;</p><p>2. for ER&#x003b2; &#x02013; a polyclonal rabbit antibody in which immunogen corresponds to NH2-terminus of the human ER&#x003b2;, and, according to the manufacturer, the sequence used is conserved in all known isoforms (Chemicon International, Temecula, CA; catalog No AB1410). This antibody was used at a dilution of 1:500 and overnight in an incubation chamber at 4&#x000b0;C;</p><p>3. for PgR &#x02013; a monoclonal mouse antibody clone PgR636, (Dako, Glostrup, Denmark; code M 3569) was used at a dilution of 1:100 and slides were incubated at room temperature for 1 h. This antibody (according to the manufacturer) has been demonstrated by Western blot to react with both forms of the progesterone receptor: the PR-A and PR-B.</p><p>The antibody reactions were revealed using Dako EnVision&#x02122;+System-HRP. Subsequently the slides were incubated in DAB chromogen for 5 minutes at room temperature. The sections were counterstained with hematoxylin, and coverslipped.</p><p>Immunostained slides were evaluated by two independent observers in a "blinded" fashion, using light microscopy. Tumors were considered to be expressing receptors if a positive reaction (regardless of its intensity) was identified in at least 10% of the cancer cells' nuclei.</p><p>HER-2 protein was identified by means of the HecepTest&#x02122; kit (Dako). Tumors were classified as 0, 1+, 2+ or 3+ on the basis of the spread and intensity of membranous staining in invasive portions of the cancer. Tumors showing staining reactions in class 3+ were considered to be over-expressing HER-2. In the case of the 2+ results obtained, suggestive of over-expression of the HER-2 protein, amplification of the <italic>c-erbB2 </italic>gene was tested by the application of fluorescent in-situ hybridization (FISH). Cases with an immunohistochemistry result of 2+ but without amplification of the gene, as tested by FISH, were not considered to be over-expressing HER2.</p><p>To assess dependences Fisher' Exact Test (for 2 &#x000d7; 2 contingency tables) and the Fisher-Freeman-Halton (for larger contingency tables) test were applied. Significance was accepted at <italic>P </italic>&#x0003c; 0.05.</p></sec><sec><title>Results</title><p>The clinicopathological characteristics of breast cancer patients with mutated <italic>BRCA1 </italic>gene and those of the control group are shown in Table <xref ref-type="table" rid="T1">1</xref>. <italic>BRCA1 </italic>gene mutations in the study group were identified as follows: 5382insC (77.5%), C61G (20.4%) and 4153delA (2%).</p><table-wrap position="float" id="T1"><label>Table 1</label><caption><p>Clinicopathological characteristics of patient cohorts</p></caption><table frame="hsides" rules="groups"><thead><tr><td align="left">Parameter</td><td align="left">BRCA1-associated breast cancers n = 48</td><td align="left">Control group n = 120</td><td align="left"><italic>P</italic>-value</td></tr></thead><tbody><tr><td align="left">Age</td><td></td><td></td><td></td></tr><tr><td align="left">&#x02003;median (range)</td><td align="left">45 (29 &#x02013; 68)</td><td align="left">57 (38 &#x02013; 85)</td><td align="left">&#x0003c;0.0001</td></tr><tr><td align="left">Age &#x0003e; 50 years</td><td align="left">16 (33%)</td><td align="left">82 (68%)</td><td></td></tr><tr><td></td><td></td><td></td><td></td></tr><tr><td align="left">Histological type</td><td></td><td></td><td></td></tr><tr><td align="left">&#x02003;invasive ductal</td><td align="left">42 (87%)</td><td align="left">103 (85.8%)</td><td align="left">0.7993</td></tr><tr><td align="left">&#x02003;invasive lobular</td><td align="left">1 (2%)</td><td align="left">10 (8.3%)</td><td align="left">0.14</td></tr><tr><td align="left">&#x02003;medullary like</td><td align="left">5 (10%)</td><td align="left">0</td><td align="left">&#x0003c; 0.001</td></tr><tr><td align="left">&#x02003;other</td><td align="left">0</td><td align="left">9 (7.5%)</td><td align="left">&#x0003c; 0.001</td></tr><tr><td></td><td></td><td></td><td></td></tr><tr><td align="left">Tumor grade</td><td></td><td></td><td></td></tr><tr><td align="left">&#x02003;I</td><td align="left">1 (2.0%)</td><td align="left">36 (29%)</td><td align="left">&#x0003c;0.001</td></tr><tr><td align="left">&#x02003;II</td><td align="left">11 (22.9%)</td><td align="left">53 (44.1%)</td><td align="left">0.0122</td></tr><tr><td align="left">&#x02003;III</td><td align="left">27 (56.2%)</td><td align="left">26 (21.7%)</td><td align="left">&#x0003c;0.0001</td></tr><tr><td align="left">&#x02003;unknown</td><td align="left">9 (18.7%)</td><td align="left">5 (4.2%)</td><td align="left">0.0017</td></tr><tr><td></td><td></td><td></td><td></td></tr><tr><td align="left">Tumor size</td><td></td><td></td><td></td></tr><tr><td align="left">&#x02003;median</td><td align="left">2.2</td><td align="left">3.0</td><td align="left">0.14</td></tr><tr><td align="left">&#x02003;&#x02264; 2 cm</td><td align="left">28 (58.3%)</td><td align="left">53 (44.1%)</td><td align="left">0.102</td></tr><tr><td align="left">&#x02003;&#x0003e; 2 cm &#x02264; 5 cm</td><td align="left">16 (33.3%)</td><td align="left">50 (41.6%)</td><td align="left">0.282</td></tr><tr><td align="left">&#x02003;&#x0003e; 5 cm</td><td align="left">3 (6.2%)</td><td align="left">17 (14.1%)</td><td align="left">0.147</td></tr><tr><td align="left">&#x02003;unknown</td><td align="left">1 (2.0%)</td><td align="left">0</td><td></td></tr><tr><td></td><td></td><td></td><td></td></tr><tr><td align="left">Lymph node</td><td></td><td></td><td></td></tr><tr><td align="left">&#x02003;negative</td><td align="left">34 (70.8%)</td><td align="left">52 (43.3%)</td><td align="left">0.001</td></tr><tr><td align="left">&#x02003;positive &#x02264; 3</td><td align="left">8 (16.6%)</td><td align="left">38 (31.6%)</td><td align="left">0.015</td></tr><tr><td align="left">&#x02003;positive &#x0003e;3</td><td align="left">4 (8.3%)</td><td align="left">22 (18.0%)</td><td align="left">0.104</td></tr><tr><td align="left">&#x02003;unknown</td><td align="left">2 (4.1%)</td><td align="left">8 (6.6%)</td><td></td></tr><tr><td></td><td></td><td></td><td></td></tr><tr><td align="left">Bilateral breast cancer</td><td align="left">13 (27.1%)</td><td align="left">2 (1.7%)</td><td align="left">&#x0003c;0.0001</td></tr><tr><td></td><td></td><td></td><td></td></tr><tr><td align="left">Mutation:</td><td></td><td></td><td></td></tr><tr><td align="left">&#x02003;5382insC</td><td align="left">37 (77.5%)</td><td></td><td></td></tr><tr><td align="left">&#x02003;C61G</td><td align="left">10 (20.4%)</td><td></td><td></td></tr><tr><td align="left">&#x02003;4153delA</td><td align="left">1 (2%)</td><td></td><td></td></tr></tbody></table></table-wrap><p>The average age of patients with mutations in the <italic>BRCA1</italic>gene was 45 years, and 57 years in the control group.</p><p>Invasive ductal carcinoma (no special type) was found to occur at the same frequency in both the <italic>BRCA1</italic>-positive group as well as the control group (87% and 85.8%, respectively). Other tumor types were much less frequent, although it is noteworthy that all 5 patients with "medullary like" carcinoma came from the <italic>BRCA1 </italic>mutation carriers group (10%).</p><p>The assessment of histological malignancy was performed according to the Bloom-Richardson classification and showed that patients carrying <italic>BRCA1 </italic>mutations developed grade 3 tumors more often and had less frequent metastases to axillary lymph nodes.</p><p>In the <italic>BRCA1</italic>-positive group, the rate of patients who developed bilateral breast cancer accounted for 27.1% (13 cases). In the control group, bilateral breast cancer was found in 2 patients only (1.7%).</p><p>The presence of estrogen receptor &#x003b1; was detected in the tumors of 7 (14.5%) patients with <italic>BRCA1</italic>gene mutations and in 69 patients (57.5%) in the control group (Fig. <xref ref-type="fig" rid="F1">1</xref>).</p><fig position="float" id="F1"><label>Figure 1</label><caption><p>ER&#x003b1; immunostaining on paraffin-embedded invasive breast cancer using 1D5 Dako antibody (40&#x000d7; magnification).</p></caption><graphic xlink:href="1471-2407-8-100-1"/></fig><p>For progesterone receptors, the figures were 6 (12.5%) and 77 (64%), respectively. The expression of estrogen receptor &#x003b2; was detected in the tumors of 20 (42%) of the <italic>BRCA1</italic>-mutation patients and in 66 (55%) of the subjects in the control group (Table <xref ref-type="table" rid="T2">2</xref>) (Fig. <xref ref-type="fig" rid="F2">2</xref>).</p><table-wrap position="float" id="T2"><label>Table 2</label><caption><p>Receptor status in BRCA1-associated breast cancer and in cancer of the control group</p></caption><table frame="hsides" rules="groups"><thead><tr><td align="left">Expression of steroid receptors</td><td align="center" colspan="2">BRCA1-associated breast cancers n = 48</td><td align="center" colspan="2">Control group n = 120</td><td align="center"><italic>P</italic>-value</td></tr><tr><td></td><td align="center">n</td><td align="center">(%)</td><td align="center">n</td><td align="center">(%)</td><td></td></tr></thead><tbody><tr><td align="left">ER&#x003b1;(+)</td><td align="center">7</td><td align="center">14.5</td><td align="center">69</td><td align="center">57.5</td><td align="center">&#x0003c;0.0001</td></tr><tr><td align="left">ER&#x003b2;(+)</td><td align="center">20</td><td align="center">42</td><td align="center">66</td><td align="center">55</td><td align="center">0.129</td></tr><tr><td align="left">PgR(+)</td><td align="center">6</td><td align="center">12.5</td><td align="center">77</td><td align="center">64</td><td align="center">&#x0003c;0.0001</td></tr><tr><td align="left">HER2(+)</td><td align="center">3</td><td align="center">6.2</td><td align="center">20</td><td align="center">16.7</td><td align="center">0.064</td></tr></tbody></table></table-wrap><fig position="float" id="F2"><label>Figure 2</label><caption><p>ER&#x003b2; immunostaining on paraffin-embedded invasive breast cancer using antibody from Chemicon (40&#x000d7; magnification).</p></caption><graphic xlink:href="1471-2407-8-100-2"/></fig><p>In the group with <italic>BRCA1 </italic>mutations, the most frequently found phenotype was ER&#x003b1;(-)/ER&#x003b2;(-) observed in 52% of patients, followed by ER&#x003b1;(-)/ER&#x003b2;(+) noticed in 33.3% cases. In the control group only 14.2% of the patients presented phenotype ER&#x003b1;(-)/ER&#x003b2;(+). The most common phenotype observed in that group was ER&#x003b1;(+)/ER&#x003b2;(+) &#x02013; 40.8% (Table <xref ref-type="table" rid="T3">3</xref>).</p><table-wrap position="float" id="T3"><label>Table 3</label><caption><p>The distribution of ER&#x003b1; and ER&#x003b2; in BRCA1-associated breast cancers and in cancers of the control group</p></caption><table frame="hsides" rules="groups"><thead><tr><td align="left">Receptors' status</td><td align="center" colspan="2">BRCA1-associated breast cancers n = 48</td><td align="center" colspan="2">Control group n = 120</td><td align="center"><bold><italic>P</italic></bold></td></tr><tr><td></td><td align="center">N</td><td align="center">(%)</td><td align="center">N</td><td align="center">(%)</td><td></td></tr></thead><tbody><tr><td align="left">ER&#x003b1;(+)/ER&#x003b2;(+)</td><td align="center">4</td><td align="center">8.3</td><td align="center">49</td><td align="center">40.8</td><td align="center">&#x0003c;0.0001</td></tr><tr><td align="left">ER&#x003b1;(+)/ER&#x003b2;(-)</td><td align="center">3</td><td align="center">6.2</td><td align="center">20</td><td align="center">16.7</td><td align="center">0.086</td></tr><tr><td align="left">ER&#x003b1;(-)/ER&#x003b2;(+)</td><td align="center">16</td><td align="center">33.3</td><td align="center">17</td><td align="center">14.2</td><td align="center">0.009</td></tr><tr><td align="left">ER&#x003b1;(-)/ER&#x003b2;(-)</td><td align="center">25</td><td align="center">52</td><td align="center">34</td><td align="center">28.3</td><td align="center">0.004</td></tr></tbody></table></table-wrap><p>The over-expression of the HER-2 receptor in patients with mutated <italic>BRCA1 </italic>genes was observed only in 3 cases (6.2%). In the control group over-expression of HER-2 was found in 20 cases (16.7%).</p><p>An interesting finding of this study is that most hereditary cancers have been found to be triple-negative: ER&#x003b1;(-)/PgR(-)/HER-2(-). Such a phenotype was found in 36 cases, which accounts for 75% of the whole group of patients with a mutated <italic>BRCA1 </italic>gene. 16 patients in that group expressed ER&#x003b2; and presented the following phenotype: ER&#x003b1;(-)/PgR(-)/HER2(-)/ER&#x003b2;(+). In the control group, the triple-negative phenotype was found in 24 patients (20%) of whom 5 had tumors expressing ER&#x003b2;.</p></sec><sec><title>Discussion</title><p>In our study, patients with <italic>BRCA1 </italic>gene mutations were tested for the expression of steroid receptors (ER&#x003b2;, ER&#x003b1; and PgR) and the HER-2 receptor in breast cancer tissue. In this group, ER&#x003b2; was more common (42%), while ER&#x003b1; and PgR occurred less frequently (14.5% and 12.5% respectively). In the control group, the expression of ER&#x003b1; and PgR was 57.5 and 64%, respectively. In the case of ER&#x003b1; and PgR, the differences between the two groups were found to be statistically significant (p = 0.001). Those values are similar to those described by other authors [<xref ref-type="bibr" rid="B8">8</xref>,<xref ref-type="bibr" rid="B12">12</xref>,<xref ref-type="bibr" rid="B21">21</xref>,<xref ref-type="bibr" rid="B22">22</xref>]. In the case of ER&#x003b2;, however, the differences of expression between those two groups were small.</p><p>Most of our control group patients were tested for the presence of BRCA1 mutations. Although those tests were not performed on all the controls, this cannot influence the overall findings of the study since in Poland BRCA1 mutations (unselected for age) occur only in about 3% of all breast cancer patients [<xref ref-type="bibr" rid="B23">23</xref>].</p><p>It has been pointed out in many studies that <italic>BRCA1 </italic>positive breast cancers rarely express ER&#x003b1; [<xref ref-type="bibr" rid="B8">8</xref>-<xref ref-type="bibr" rid="B12">12</xref>,<xref ref-type="bibr" rid="B20">20</xref>,<xref ref-type="bibr" rid="B21">21</xref>]. Further confirmation of that observation comes from recent studies made with the use of the cDNA microarray technique, showing that breast cancers may vary considerably in their molecular profile [<xref ref-type="bibr" rid="B24">24</xref>,<xref ref-type="bibr" rid="B25">25</xref>]. The largest group consists of tumors with a cellular profile matching that of the inner layers of the mammary glands, such as luminal cells (luminal types) and another group consists of tumors with basal cell profiles (basal types). These two groups differ in their expression of ER&#x003b1;. The luminal types express ER&#x003b1;, while the basal types usually do not. cDNA studies of breast cancers with underlying <italic>BRCA1 </italic>gene mutations show that the most common cancer type in this group is basal [<xref ref-type="bibr" rid="B26">26</xref>]. Moreover, basal type tumors show expression of receptors for epidermal growth factor (EGFR) more often. Generally, about half of the patients with <italic>BRCA1 </italic>gene mutations present the phenotype ER(-)/HER2(-)/EGFR(+) of the basal type of tumor, which is usually associated with poor prognosis [<xref ref-type="bibr" rid="B26">26</xref>-<xref ref-type="bibr" rid="B28">28</xref>]. On the other hand, there are data that suggest that the prognosis for <italic>BRCA1</italic>-positive patients is no worse than that for patients without mutations [<xref ref-type="bibr" rid="B10">10</xref>-<xref ref-type="bibr" rid="B14">14</xref>]. This discrepancy may suggest the influence of some incompletely explored prognostic and predictive factor(s).</p><p>Recent analyses suggest that ER&#x003b2; may be an independent prognostic and predictive factor in the course of breast cancer [<xref ref-type="bibr" rid="B29">29</xref>-<xref ref-type="bibr" rid="B33">33</xref>]. However, its role has not yet been fully discovered. It is noteworthy that in our clinical material (in contrast to ER&#x003b1;) the expression of the ER&#x003b2; in tumor tissues of patients with <italic>BRCA1 </italic>gene mutations is almost as frequent as in the non-hereditary breast cancer patients. It would be interesting to test whether frequent representation of ER&#x003b2; in <italic>BRCA</italic>-positive tumors is actually responsible for the earlier reported activity of tamoxifen in the reduction of contralateral breast cancer risk.</p><p>Fan et al. showed that there is a link between estrogen receptors and the BRCA1 protein. In an <italic>in vitro </italic>study, BRCA1 protein proved to be one of the transcription regulators for active ER&#x003b1;. The transcription co-activator p300 plays an important role in this process, and its presence correlates with the ability of the BRCA1 protein to suppress the activation of ER&#x003b1; transcription [<xref ref-type="bibr" rid="B7">7</xref>].</p><p>Our study group displayed certain characteristics of hereditary breast cancer. One of these features was the young age of the patients. In this group, the average age of breast cancer diagnosis was 45 years, 12 years earlier than in the control group. The same average age at which the diagnosis was established, was reported for Spanish families and a similar age (43 years) in Markus's study of the population of Ashkenazi Jews [<xref ref-type="bibr" rid="B10">10</xref>]. Age is a well known factor influencing the expression of ER&#x003b1;. The fact that there was a 12-year difference in the average age between the <italic>BRCA1 </italic>gene mutations group and the control group must have some influence on the reported ER&#x003b1; expression in our study. Regarding ER&#x003b2; expression, however, we believe that difference bears no material significance on the result. Our opinion is based on the fact that numerous studies have indicated that the expression of ER&#x003b2; is not age-dependent.</p><p>In both groups, the most frequent histological diagnosis was that of ductal carcinoma (87% and 85.8%, respectively). Another common histological type of breast cancer found in the mutation carriers group was "medullary like" carcinoma (10%). In the control group, however, not a single case of that type of cancer was identified. A higher rate of "medullary like" carcinoma is typical of <italic>BRCA1 </italic>mutation carriers and this diagnosis is associated with a relatively good prognosis [<xref ref-type="bibr" rid="B34">34</xref>,<xref ref-type="bibr" rid="B35">35</xref>]. Consequently, it was believed that this diagnosis positively affected the prognosis for <italic>BRCA1</italic>-positive patients. Unfortunately, a recent study failed to confirm that finding [<xref ref-type="bibr" rid="B36">36</xref>].</p><p>Patients with hereditary disease have been found to develop bilateral breast cancer more often. Our study has confirmed this observation as it has been found that bilateral breast cancer affected 13 patients of the study group (27.1%).</p><p>The above characteristics of hereditary breast cancer have been frequently described in the literature and are consistent with the previously published data. Little, however, has been said regarding the expression of ER&#x003b2;. This appears to have been mentioned only once in a letter to the Editor of the Journal of Clinical Oncology which reported on estrogen receptor-beta expression in hereditary breast cancer where positive staining for ER&#x003b2; was detectable in 94% (15 of 16) of <italic>BRCA1 </italic>associated breast cancers [<xref ref-type="bibr" rid="B37">37</xref>].</p><p>In our study, ER&#x003b2; expression was present in 42% of <italic>BRCA1 </italic>mutation carriers. This seems to be important as it may explain the protective effect of tamoxifen in the prevention of contralateral tumor development in <italic>BRCA1 </italic>mutation carriers.</p><p>Out of the hereditary cancer patients in our study group, 75% were found to be triple-negative, lacking ER&#x003b1;, PgR and HER-2 over-expression. Unfortunately, at the current state of the art, neither hormonal therapy, nor immunotherapy (trastuzumab) in an adjuvant setting, can be offered to those patients.</p><p>Gruvberger-Saal et al [<xref ref-type="bibr" rid="B38">38</xref>] reported that the expression of ER&#x003b2; is an independent marker for favourable prognosis after adjuvant tamoxifen treatment in ER&#x003b1; negative breast cancer patients. Bearing in mind that as many as 44% of the triple-negative patients in our study expressed ER&#x003b2;, we propose that hormone therapy might be used in the treatment of <italic>BRCA1 </italic>mutation carriers expressing the ER&#x003b1;(-)/PgR(-/HER2(-)/ER&#x003b2;(+) phenotype.</p><p>The results obtained in our study show that the expression of ER&#x003b2; in <italic>BRCA1 </italic>gene mutation carriers is statistically higher than the expression of ER&#x003b1;. This may be why tamoxifen has proven to be effective in preventing the development of contralateral breast cancer in <italic>BRCA1 </italic>mutation carriers. Consequently, testing patients carrying <italic>BRCA1 </italic>mutations for the presence of ER&#x003b2; might help to identify those who could benefit from endocrine therapy.</p></sec><sec><title>Conclusion</title><p>In the case of <italic>BRCA1</italic>-associated tumors the expression of ER&#x003b2; was significantly higher than the expression of ER&#x003b1;. This may explain the effectiveness of tamoxifen in preventing contralateral breast cancer development in <italic>BRCA1 </italic>mutation carriers.</p></sec><sec><title>Abbreviations</title><p>ER &#x02013; estrogen receptor</p><p>ER&#x003b1; &#x02013; estrogen receptor alpha</p><p>ER&#x003b2; &#x02013; estrogen receptor beta</p><p>PgR &#x02013; progesterone receptor</p><p><italic>BRCA1 </italic>&#x02013; breast cancer associated gene</p><p><italic>BRCA2 </italic>&#x02013; breast cancer associated gene</p><p>PCR &#x02013; polymerase chain reaction</p><p>HER-2 &#x02013; human epidermal growth factor receptor-2</p><p>SERM &#x02013; selective estrogen receptor modulator</p><p>IHC &#x02013; immunohistochemistry</p><p>ASA-PCR &#x02013; amplicon sequence analysis &#x02013; polymerase chain reaction</p><p>RFLP-PCR &#x02013; restriction fragment length polymorphism &#x02013; polymerase chain reaction</p><p>FISH &#x02013; fluorescent hybridization in situ</p><p>EGFR &#x02013; epidermal growth factor receptor</p><p>cDNA &#x02013; complementary DNA</p></sec><sec><title>Competing interests</title><p>The author(s) declare that they have no competing interests.</p></sec><sec><title>Authors' contributions</title><p>ML conceived, designed and performed the study, coordinated the work and drafted the manuscript, KR participated in the draft of the manuscript, VF performed IHC tests, DG and MS carried out genetic tests, RK reviewed the manuscript and offered some comments, JB interpreted histopathological and IHC test results. All authors have read and approved the final manuscript.</p></sec><sec><title>Pre-publication history</title><p>The pre-publication history for this paper can be accessed here:</p><p><ext-link ext-link-type="uri" xlink:href="http://www.biomedcentral.com/1471-2407/8/100/prepub"/></p></sec></body><back><ref-list><ref id="B1"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Hall</surname><given-names>JM</given-names></name><name><surname>Lee</surname><given-names>MK</given-names></name><name><surname>Newman</surname><given-names>B</given-names></name><name><surname>Morrow</surname><given-names>JE</given-names></name><name><surname>Anderson</surname><given-names>LA</given-names></name><name><surname>Huey</surname><given-names>B</given-names></name><name><surname>King</surname><given-names>MC</given-names></name></person-group><article-title>Linkage of early-onset familial breast cancer to chromosome 17q21</article-title><source>Science</source><year>1990</year><volume>250</volume><fpage>1684</fpage><lpage>1689</lpage><pub-id pub-id-type="pmid">2270482</pub-id><pub-id pub-id-type="doi">10.1126/science.2270482</pub-id></citation></ref><ref id="B2"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Krainer</surname><given-names>M</given-names></name><name><surname>Silvia-Arrieta</surname><given-names>S</given-names></name><name><surname>Fitzgerald</surname><given-names>MG</given-names></name><name><surname>Shimada</surname><given-names>A</given-names></name><name><surname>Ishioka</surname><given-names>C</given-names></name><name><surname>Kanamaru</surname><given-names>R</given-names></name><name><surname>MacDonald</surname><given-names>DJ</given-names></name><name><surname>Unsal</surname><given-names>H</given-names></name><name><surname>Finkelstein</surname><given-names>DM</given-names></name><name><surname>Bowcock</surname><given-names>A</given-names></name><name><surname>Isselbacher</surname><given-names>KJ</given-names></name><name><surname>Haber</surname><given-names>DA</given-names></name></person-group><article-title>Differential contributions of <italic>BRCA1 </italic>and BRCA2 to early-onset breast cancer</article-title><source>N Engl J Med</source><year>1997</year><volume>336</volume><fpage>1416</fpage><lpage>1421</lpage><pub-id pub-id-type="pmid">9145678</pub-id><pub-id pub-id-type="doi">10.1056/NEJM199705153362003</pub-id></citation></ref><ref id="B3"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Struewing</surname><given-names>JP</given-names></name><name><surname>Hartge</surname><given-names>P</given-names></name><name><surname>Wacholder</surname><given-names>S</given-names></name><name><surname>Baker</surname><given-names>SM</given-names></name><name><surname>Berlin</surname><given-names>M</given-names></name><name><surname>McAdams</surname><given-names>M</given-names></name><name><surname>Timmerman</surname><given-names>MM</given-names></name><name><surname>Brody</surname><given-names>LC</given-names></name><name><surname>Tucker</surname><given-names>MA</given-names></name></person-group><article-title>The risk of cancer associated with specific mutations of <italic>BRCA1 </italic>and BRCA2 among Ashkenazi Jews</article-title><source>N Engl J Med</source><year>1997</year><volume>336</volume><fpage>1401</fpage><lpage>1408</lpage><pub-id pub-id-type="pmid">9145676</pub-id><pub-id pub-id-type="doi">10.1056/NEJM199705153362001</pub-id></citation></ref><ref id="B4"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Miki</surname><given-names>Y</given-names></name><name><surname>Swensen</surname><given-names>J</given-names></name><name><surname>Shattuck-Eidens</surname><given-names>D</given-names></name><name><surname>Futreal</surname><given-names>PA</given-names></name><name><surname>Harshman</surname><given-names>K</given-names></name><name><surname>Tavtigian</surname><given-names>S</given-names></name><name><surname>Liu</surname><given-names>Q</given-names></name><name><surname>Cochran</surname><given-names>C</given-names></name><name><surname>Bennett</surname><given-names>LM</given-names></name><name><surname>Ding</surname><given-names>W</given-names></name></person-group><article-title>A strong candidate for the breast and ovarian cancer susceptibility gene <italic>BRCA1</italic></article-title><source>Science</source><year>1994</year><volume>266</volume><fpage>66</fpage><lpage>71</lpage><pub-id pub-id-type="pmid">7545954</pub-id><pub-id pub-id-type="doi">10.1126/science.7545954</pub-id></citation></ref><ref id="B5"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Wooster</surname><given-names>R</given-names></name><name><surname>Bignell</surname><given-names>G</given-names></name><name><surname>Lancaster</surname><given-names>J</given-names></name><name><surname>Swift</surname><given-names>S</given-names></name><name><surname>Seal</surname><given-names>S</given-names></name><name><surname>Mangion</surname><given-names>J</given-names></name><name><surname>Collins</surname><given-names>N</given-names></name><name><surname>Gregory</surname><given-names>S</given-names></name><name><surname>Gumbs</surname><given-names>C</given-names></name><name><surname>Micklem</surname><given-names>G</given-names></name><name><surname>Berfoot</surname><given-names>R</given-names></name><name><surname>Hamoudi</surname><given-names>R</given-names></name><name><surname>Patel</surname><given-names>S</given-names></name><name><surname>Rices</surname><given-names>C</given-names></name><name><surname>Biggs</surname><given-names>P</given-names></name><name><surname>Hashim</surname><given-names>J</given-names></name><name><surname>Smith</surname><given-names>A</given-names></name><name><surname>Connor</surname><given-names>F</given-names></name><name><surname>Arason</surname><given-names>A</given-names></name><name><surname>Gudmundsson</surname><given-names>J</given-names></name><name><surname>Ficenec</surname><given-names>D</given-names></name><name><surname>Kelsell</surname><given-names>D</given-names></name><name><surname>Fordtonin</surname><given-names>DP</given-names></name><name><surname>Bishop</surname><given-names>TD</given-names></name><name><surname>Spurr</surname><given-names>NK</given-names></name><name><surname>Ponder</surname><given-names>BAJ</given-names></name><name><surname>Eeles</surname><given-names>R</given-names></name><name><surname>Peto</surname><given-names>J</given-names></name><name><surname>Devilee</surname><given-names>P</given-names></name><name><surname>Cornelisse</surname><given-names>C</given-names></name><name><surname>Lynch</surname><given-names>H</given-names></name><name><surname>Narod</surname><given-names>S</given-names></name><name><surname>Lenoir</surname><given-names>G</given-names></name><name><surname>egilsson</surname><given-names>V</given-names></name><name><surname>barkadottir</surname><given-names>RB</given-names></name><name><surname>Easton</surname><given-names>DF</given-names></name><name><surname>Bentley</surname><given-names>DR</given-names></name><name><surname>Futreal</surname><given-names>A</given-names></name><name><surname>Ashworth</surname><given-names>A</given-names></name><name><surname>Stratton</surname><given-names>MR</given-names></name></person-group><article-title>Identification of the breast cancer susceptibility gene <italic>BRCA2</italic></article-title><source>Nature</source><year>1995</year><volume>378</volume><fpage>789</fpage><lpage>792</lpage><pub-id pub-id-type="pmid">8524414</pub-id><pub-id pub-id-type="doi">10.1038/378789a0</pub-id></citation></ref><ref id="B6"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Martin</surname><given-names>AM</given-names></name><name><surname>Weber</surname><given-names>BL</given-names></name></person-group><article-title>Genetic and hormonal risk factor in breast cancer</article-title><source>J Natl Cancer Inst</source><year>2000</year><volume>92</volume><fpage>1126</fpage><lpage>35</lpage><pub-id pub-id-type="pmid">10904085</pub-id><pub-id pub-id-type="doi">10.1093/jnci/92.14.1126</pub-id></citation></ref><ref id="B7"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Fan</surname><given-names>S</given-names></name><name><surname>Ma</surname><given-names>YX</given-names></name><name><surname>Wang</surname><given-names>C</given-names></name><name><surname>Yuan</surname><given-names>R-Q</given-names></name><name><surname>Meng</surname><given-names>Q</given-names></name><name><surname>Wang</surname><given-names>L-A</given-names></name><name><surname>Erdos</surname><given-names>M</given-names></name><name><surname>Goldberg</surname><given-names>ID</given-names></name><name><surname>Webb</surname><given-names>P</given-names></name><name><surname>Kushner</surname><given-names>PJ</given-names></name><name><surname>Pestell</surname><given-names>RG</given-names></name><name><surname>Rosen</surname><given-names>EM</given-names></name></person-group><article-title>p300 Modulates the <italic>BRCA1 </italic>inhibition of estrogen receptor activity</article-title><source>Cancer Res</source><year>2002</year><volume>62</volume><fpage>141</fpage><lpage>151</lpage><pub-id pub-id-type="pmid">11782371</pub-id></citation></ref><ref id="B8"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Lakhani</surname><given-names>SR</given-names></name><name><surname>van de Vijver</surname><given-names>MJ</given-names></name><name><surname>Jacquemier</surname><given-names>J</given-names></name><name><surname>Thomas</surname><given-names>J</given-names></name><name><surname>Anderson</surname><given-names>TJ</given-names></name><name><surname>Osin</surname><given-names>PP</given-names></name><name><surname>McGuffog</surname><given-names>L</given-names></name><name><surname>Easton</surname><given-names>DF</given-names></name></person-group><article-title>The pathology of familial breast cancer: predictive value of immunohistochemical markers estrogen receptor, progesterone receptor, HER-2, and p53 in patients with mutations in <italic>BRCA1 </italic>and <italic>BRCA2</italic></article-title><source>J Clin Oncol</source><year>2002</year><volume>20</volume><fpage>2310</fpage><lpage>2318</lpage><pub-id pub-id-type="pmid">11981002</pub-id><pub-id pub-id-type="doi">10.1200/JCO.2002.09.023</pub-id></citation></ref><ref id="B9"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Honrado</surname><given-names>E</given-names></name><name><surname>Benitez</surname><given-names>J</given-names></name><name><surname>Palacios</surname><given-names>J</given-names></name></person-group><article-title>The pathology of hereditary breast cancer</article-title><source>Hereditary Cancer Clin Pract</source><year>2004</year><volume>2</volume><fpage>131</fpage><lpage>138</lpage></citation></ref><ref id="B10"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Marcus</surname><given-names>JN</given-names></name><name><surname>Watson</surname><given-names>P</given-names></name><name><surname>Page</surname><given-names>DL</given-names></name><name><surname>Narod</surname><given-names>SA</given-names></name><name><surname>Lenoir</surname><given-names>GM</given-names></name><name><surname>Tonin</surname><given-names>P</given-names></name><name><surname>Linder-Stephenson</surname><given-names>L</given-names></name><name><surname>Salerno</surname><given-names>G</given-names></name><name><surname>Conway</surname><given-names>TA</given-names></name><name><surname>Lynch</surname><given-names>HT</given-names></name></person-group><article-title>Hereditary breast cancer. Pathology, prognosis, and <italic>BRCA1 </italic>and BRCA2 gene linkage</article-title><source>Cancer</source><year>1996</year><volume>77</volume><fpage>697</fpage><lpage>709</lpage><pub-id pub-id-type="pmid">8616762</pub-id><pub-id pub-id-type="doi">10.1002/(SICI)1097-0142(19960215)77:4&#x0003c;697::AID-CNCR16&#x0003e;3.0.CO;2-W</pub-id></citation></ref><ref id="B11"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Porter</surname><given-names>DE</given-names></name><name><surname>Cohen</surname><given-names>BB</given-names></name><name><surname>Wallace</surname><given-names>MR</given-names></name><name><surname>Smyth</surname><given-names>E</given-names></name><name><surname>Chetty</surname><given-names>U</given-names></name><name><surname>Dixon</surname><given-names>JM</given-names></name><name><surname>Steel</surname><given-names>CM</given-names></name><name><surname>Carter</surname><given-names>DC</given-names></name></person-group><article-title>Breast cancer incidence, penetrance and survival in probable carriers of <italic>BRCA1 </italic>gene mutation in families linked to <italic>BRCA1 </italic>on chromosome 17q12-21</article-title><source>Br J Surg</source><year>1994</year><volume>10</volume><fpage>1512</fpage><lpage>1515</lpage><pub-id pub-id-type="pmid">7820489</pub-id><pub-id pub-id-type="doi">10.1002/bjs.1800811038</pub-id></citation></ref><ref id="B12"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Verhoog</surname><given-names>LC</given-names></name><name><surname>Brekelmans</surname><given-names>CT</given-names></name><name><surname>Seynaeve</surname><given-names>C</given-names></name><name><surname>van den Bosch </surname><given-names>LM</given-names></name><name><surname>Dahmen</surname><given-names>G</given-names></name><name><surname>van Geel</surname><given-names>AN</given-names></name><name><surname>Bartels</surname><given-names>CC</given-names></name><name><surname>Tilanus-Linthorst</surname><given-names>MM</given-names></name><name><surname>Wagner</surname><given-names>A</given-names></name><name><surname>Devilee</surname><given-names>P</given-names></name><name><surname>Halley</surname><given-names>DJJ</given-names></name><name><surname>van den Ouweland</surname><given-names>AM</given-names></name><name><surname>Meijers-Heijboer</surname><given-names>EJ</given-names></name><name><surname>Klijn</surname><given-names>JGM</given-names></name></person-group><article-title>Survival and tumor characteristics of breast-cancer patients with germline mutations of <italic>BRCA1</italic></article-title><source>Lancet</source><year>1998</year><volume>351</volume><fpage>316</fpage><lpage>321</lpage><pub-id pub-id-type="pmid">9652611</pub-id><pub-id pub-id-type="doi">10.1016/S0140-6736(97)07065-7</pub-id></citation></ref><ref id="B13"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Gaffney</surname><given-names>DK</given-names></name><name><surname>Brohet</surname><given-names>RM</given-names></name><name><surname>Lewis</surname><given-names>CM</given-names></name><name><surname>Holden</surname><given-names>JA</given-names></name><name><surname>Buys</surname><given-names>SS</given-names></name><name><surname>Neuhausen</surname><given-names>SL</given-names></name><name><surname>Steele</surname><given-names>L</given-names></name><name><surname>Avizonis</surname><given-names>V</given-names></name><name><surname>Stewart</surname><given-names>JR</given-names></name><name><surname>Cannon-Albright</surname><given-names>LA</given-names></name></person-group><article-title>Response to radiation therapy and prognosis in breast cancer patients with <italic>BRCA1 </italic>and BRCA2 mutations</article-title><source>Radiother Oncol</source><year>1998</year><volume>47</volume><fpage>129</fpage><lpage>136</lpage><pub-id pub-id-type="pmid">9683359</pub-id><pub-id pub-id-type="doi">10.1016/S0167-8140(98)00023-1</pub-id></citation></ref><ref id="B14"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Stoppa-Lyonnet</surname><given-names>D</given-names></name><name><surname>Ansquer</surname><given-names>Y</given-names></name><name><surname>Dreyfus</surname><given-names>H</given-names></name><name><surname>Gautier</surname><given-names>C</given-names></name><name><surname>Gauthier-Villars</surname><given-names>M</given-names></name><name><surname>Bourstyn</surname><given-names>E</given-names></name><name><surname>Clough</surname><given-names>KB</given-names></name><name><surname>Magdel&#x000e9;nat</surname><given-names>H</given-names></name><name><surname>Pouillart</surname><given-names>P</given-names></name><name><surname>Vincent-Salomon</surname><given-names>A</given-names></name><name><surname>Fourquet</surname><given-names>A</given-names></name><name><surname>Asselain</surname><given-names>B</given-names></name></person-group><article-title>Familial Invasive breast cancer: worse outcome related to <italic>BRCA1 </italic>mutations</article-title><source>J Clin Oncol</source><year>2000</year><volume>18</volume><fpage>4053</fpage><lpage>4059</lpage><pub-id pub-id-type="pmid">11118466</pub-id></citation></ref><ref id="B15"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Robson</surname><given-names>ME</given-names></name><name><surname>Chappuis</surname><given-names>PO</given-names></name><name><surname>Satagopan</surname><given-names>J</given-names></name><name><surname>Wong</surname><given-names>N</given-names></name><name><surname>Boyd</surname><given-names>J</given-names></name><name><surname>Goffin</surname><given-names>JR</given-names></name><name><surname>Hudis</surname><given-names>C</given-names></name><name><surname>Roberge</surname><given-names>D</given-names></name><name><surname>Norton</surname><given-names>L</given-names></name><name><surname>B&#x000e9;gin</surname><given-names>LR</given-names></name><name><surname>Offit</surname><given-names>K</given-names></name><name><surname>Foulkes</surname><given-names>WD</given-names></name></person-group><article-title>A combined analysis of outcome following breast cancer: Differences in survival based on <italic>BRCA1 </italic>/BRCA2 mutation status and administration of adjuvant treatment</article-title><source>Breast Cancer Res</source><year>2004</year><volume>6</volume><fpage>R8</fpage><lpage>R17</lpage><pub-id pub-id-type="pmid">14680495</pub-id><pub-id pub-id-type="doi">10.1186/bcr658</pub-id></citation></ref><ref id="B16"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Narod</surname><given-names>SA</given-names></name><name><surname>Brunet</surname><given-names>JS</given-names></name><name><surname>Ghadirian</surname><given-names>P</given-names></name><name><surname>Robson</surname><given-names>M</given-names></name><name><surname>Heimdal</surname><given-names>K</given-names></name><name><surname>Neuhausen</surname><given-names>SL</given-names></name><name><surname>Stoppa-Lyonnet</surname><given-names>D</given-names></name><name><surname>Lerman</surname><given-names>C</given-names></name><name><surname>Pasini</surname><given-names>B</given-names></name><name><surname>de los Rios</surname><given-names>P</given-names></name><name><surname>Weber</surname><given-names>B</given-names></name><name><surname>Lynch</surname><given-names>H</given-names></name></person-group><article-title>Tamoxifen and risk of contralateral breast cancer in <italic>BRCA1 </italic>and BRCA2 mutation carriers: a case-control study</article-title><source>Lancet</source><year>2000</year><volume>356</volume><fpage>1876</fpage><lpage>1881</lpage><pub-id pub-id-type="pmid">11130383</pub-id><pub-id pub-id-type="doi">10.1016/S0140-6736(00)03258-X</pub-id></citation></ref><ref id="B17"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Kuiper</surname><given-names>GG</given-names></name><name><surname>Enmark</surname><given-names>E</given-names></name><name><surname>Pelto-Huikko</surname><given-names>M</given-names></name><name><surname>Nilsson</surname><given-names>S</given-names></name><name><surname>Gustaffson</surname><given-names>JA</given-names></name></person-group><article-title>Cloning of a novel receptor expressed in rat prostate and ovary</article-title><source>Proc Natl Acad Sci USA</source><year>1996</year><volume>93</volume><fpage>5925</fpage><lpage>5930</lpage><pub-id pub-id-type="pmid">8650195</pub-id><pub-id pub-id-type="doi">10.1073/pnas.93.12.5925</pub-id></citation></ref><ref id="B18"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Mosselman</surname><given-names>S</given-names></name><name><surname>Polman</surname><given-names>J</given-names></name><name><surname>Dijkema</surname><given-names>R</given-names></name></person-group><article-title>ER-&#x003b2;: identification and characterisation of a novel human estrogen receptor</article-title><source>FEBS Lett</source><year>1996</year><volume>392</volume><fpage>49v53</fpage><pub-id pub-id-type="pmid">8769313</pub-id><pub-id pub-id-type="doi">10.1016/0014-5793(96)00782-X</pub-id></citation></ref><ref id="B19"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Barkhem</surname><given-names>T</given-names></name><name><surname>Carlsson</surname><given-names>B</given-names></name><name><surname>Nilsson</surname><given-names>Y</given-names></name><name><surname>Enmark</surname><given-names>E</given-names></name><name><surname>Gustafsson</surname><given-names>J-&#x000c5;</given-names></name><name><surname>Nilsson</surname><given-names>S</given-names></name></person-group><article-title>Differential response of estrogen receptor alpha and estrogen receptor &#x003b2; to partial estrogen agonists/antagonists</article-title><source>Mol Pharmacol</source><year>1998</year><volume>54</volume><fpage>105</fpage><lpage>112</lpage><pub-id pub-id-type="pmid">9658195</pub-id></citation></ref><ref id="B20"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Speirs</surname><given-names>V</given-names></name></person-group><article-title>Oestrogen receptor &#x003b2; in breast cancer: good, bad or still too early to tell?</article-title><source>J Pathol</source><year>2002</year><volume>197</volume><fpage>143</fpage><lpage>147</lpage><pub-id pub-id-type="pmid">12015736</pub-id><pub-id pub-id-type="doi">10.1002/path.1072</pub-id></citation></ref><ref id="B21"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Eisinger</surname><given-names>F</given-names></name><name><surname>Jacquemier</surname><given-names>J</given-names></name><name><surname>Nogues</surname><given-names>C</given-names></name><name><surname>Birnbaum</surname><given-names>D</given-names></name><name><surname>Sobol</surname><given-names>H</given-names></name></person-group><article-title>Steroid receptors in hereditary breast carcinomas associated with BRC1 or BRCA2 mutations or unknown susceptibility genes</article-title><source>Cancer</source><year>1999</year><volume>85</volume><fpage>2291</fpage><lpage>2295</lpage><pub-id pub-id-type="pmid">10326710</pub-id><pub-id pub-id-type="doi">10.1002/(SICI)1097-0142(19990515)85:10&#x0003c;2291::AID-CNCR26&#x0003e;3.0.CO;2-9</pub-id></citation></ref><ref id="B22"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Lynch</surname><given-names>BJ</given-names></name><name><surname>Holden</surname><given-names>JA</given-names></name><name><surname>Buys</surname><given-names>SS</given-names></name><name><surname>Neuhausen</surname><given-names>SL</given-names></name><name><surname>Gaffney</surname><given-names>DK</given-names></name></person-group><article-title>Pathobiologic characteristics of hereditary breast cancer</article-title><source>Hum Pathol</source><year>1998</year><volume>29</volume><fpage>1140</fpage><lpage>1144</lpage><pub-id pub-id-type="pmid">9781655</pub-id><pub-id pub-id-type="doi">10.1016/S0046-8177(98)90427-0</pub-id></citation></ref><ref id="B23"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>G&#x000f3;rski</surname><given-names>B</given-names></name><name><surname>Cybulski</surname><given-names>C</given-names></name><name><surname>Huzarski</surname><given-names>T</given-names></name><name><surname>Byrski</surname><given-names>T</given-names></name><name><surname>Gronwald</surname><given-names>J</given-names></name><name><surname>Jakubowska</surname><given-names>A</given-names></name><name><surname>Stawicka</surname><given-names>M</given-names></name><name><surname>Grodecka-Gazdecka</surname><given-names>S</given-names></name><name><surname>Szwiec</surname><given-names>M</given-names></name><name><surname>Urba&#x00144;ski</surname><given-names>K</given-names></name><name><surname>Mitu&#x0015b;</surname><given-names>J</given-names></name><name><surname>Marczyk</surname><given-names>E</given-names></name><name><surname>Dziuba</surname><given-names>J</given-names></name><name><surname>Wandzel</surname><given-names>P</given-names></name><name><surname>Surdyka</surname><given-names>D</given-names></name><name><surname>Haus</surname><given-names>O</given-names></name><name><surname>Janiszewska</surname><given-names>H</given-names></name><name><surname>D&#x00119;bniak</surname><given-names>T</given-names></name><name><surname>To&#x00142;oczko-Grabarek</surname><given-names>A</given-names></name><name><surname>Medrek</surname><given-names>K</given-names></name><name><surname>Masoj&#x00107;</surname><given-names>B</given-names></name><name><surname>Mierzejewski</surname><given-names>M</given-names></name><name><surname>Kowalska</surname><given-names>E</given-names></name><name><surname>Narod</surname><given-names>SA</given-names></name><name><surname>Lubi&#x00144;ski</surname><given-names>J</given-names></name></person-group><article-title>Breast cancer predisposing alleles in Poland</article-title><source>Breast Cancer Res Treat</source><year>2005</year><volume>92</volume><fpage>19</fpage><lpage>24</lpage><pub-id pub-id-type="pmid">15980987</pub-id><pub-id pub-id-type="doi">10.1007/s10549-005-1409-1</pub-id></citation></ref><ref id="B24"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>S&#x000f8;rlie</surname><given-names>T</given-names></name><name><surname>Perou</surname><given-names>CHM</given-names></name><name><surname>Tibshirani</surname><given-names>R</given-names></name><name><surname>Aas</surname><given-names>T</given-names></name><name><surname>Geisler</surname><given-names>S</given-names></name><name><surname>Johnsen</surname><given-names>H</given-names></name><name><surname>Hastie</surname><given-names>T</given-names></name><name><surname>Eisen</surname><given-names>MB</given-names></name><name><surname>van de Rijn</surname><given-names>M</given-names></name><name><surname>Jeffrey</surname><given-names>SS</given-names></name><name><surname>Thorsen</surname><given-names>T</given-names></name><name><surname>Quist</surname><given-names>H</given-names></name><name><surname>Matese</surname><given-names>JC</given-names></name><name><surname>Brown</surname><given-names>PO</given-names></name><name><surname>Botstein</surname><given-names>D</given-names></name><name><surname>Eystein L&#x000f8;nning</surname><given-names>P</given-names></name><name><surname>B&#x000f8;rresen-Dale</surname><given-names>AL</given-names></name></person-group><article-title>Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications</article-title><source>PNAS</source><year>2001</year><volume>98</volume><fpage>10869</fpage><lpage>10874</lpage><pub-id pub-id-type="pmid">11553815</pub-id><pub-id pub-id-type="doi">10.1073/pnas.191367098</pub-id></citation></ref><ref id="B25"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>S&#x000f8;rlie</surname><given-names>T</given-names></name><name><surname>Tibishirani</surname><given-names>R</given-names></name><name><surname>Parker</surname><given-names>J</given-names></name><name><surname>Hastie</surname><given-names>T</given-names></name><name><surname>Marron</surname><given-names>JS</given-names></name><name><surname>Nobel</surname><given-names>A</given-names></name><name><surname>Deng</surname><given-names>S</given-names></name><name><surname>Johnsen</surname><given-names>H</given-names></name><name><surname>Pesich</surname><given-names>R</given-names></name><name><surname>Geisler</surname><given-names>S</given-names></name><name><surname>Demeter</surname><given-names>J</given-names></name><name><surname>Perou</surname><given-names>CM</given-names></name><name><surname>Lonning</surname><given-names>PE</given-names></name><name><surname>Brown</surname><given-names>PO</given-names></name><name><surname>Borresen-Dale</surname><given-names>A-L</given-names></name><name><surname>Botstein</surname><given-names>D</given-names></name></person-group><article-title>Repeated observation of breast tumor subtypes in independent gene expression data sets</article-title><source>PNAS</source><year>2003</year><volume>100</volume><fpage>8418</fpage><lpage>8423</lpage><pub-id pub-id-type="pmid">12829800</pub-id><pub-id pub-id-type="doi">10.1073/pnas.0932692100</pub-id></citation></ref><ref id="B26"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Foulkes</surname><given-names>WD</given-names></name><name><surname>Stefansson</surname><given-names>IM</given-names></name><name><surname>Chappuis</surname><given-names>PO</given-names></name><name><surname>B&#x000e9;gin</surname><given-names>LR</given-names></name><name><surname>Goffin</surname><given-names>JR</given-names></name><name><surname>Wong</surname><given-names>N</given-names></name><name><surname>Trudel</surname><given-names>M</given-names></name><name><surname>Akslen</surname><given-names>LA</given-names></name></person-group><article-title>Germline <italic>BRCA1 </italic>mutations and a basal epithelial phenotype in breast cancer</article-title><source>J Natl Cancer Inst</source><year>2003</year><volume>95</volume><fpage>1482</fpage><lpage>1485</lpage><pub-id pub-id-type="pmid">14519755</pub-id></citation></ref><ref id="B27"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>van der Groep</surname><given-names>P</given-names></name><name><surname>Bouter</surname><given-names>A</given-names></name><name><surname>van der Zanden</surname><given-names>R</given-names></name><name><surname>Menko</surname><given-names>FH</given-names></name><name><surname>Buerger</surname><given-names>H</given-names></name><name><surname>Verheijen</surname><given-names>RHM</given-names></name><name><surname>van der Wall</surname><given-names>E</given-names></name><name><surname>van Diest</surname><given-names>PJ</given-names></name></person-group><article-title>RE: Germline <italic>BRCA1 </italic>mutations and a basal epithelial phenotype in breast cancer</article-title><source>J Natl Cancer Inst</source><year>2004</year><volume>96</volume><fpage>712</fpage><pub-id pub-id-type="pmid">15126610</pub-id></citation></ref><ref id="B28"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Faulkes</surname><given-names>WD</given-names></name><name><surname>Brunet</surname><given-names>JS</given-names></name><name><surname>Stefansson</surname><given-names>IM</given-names></name><name><surname>Straume</surname><given-names>O</given-names></name><name><surname>Chappuis</surname><given-names>PO</given-names></name><name><surname>B&#x000e9;gin</surname><given-names>LR</given-names></name><name><surname>Hamel</surname><given-names>N</given-names></name><name><surname>Goffin</surname><given-names>JR</given-names></name><name><surname>Wong</surname><given-names>N</given-names></name><name><surname>Trudel</surname><given-names>M</given-names></name><name><surname>Kapusta</surname><given-names>L</given-names></name><name><surname>Porter</surname><given-names>P</given-names></name><name><surname>Akslen</surname><given-names>LA</given-names></name></person-group><article-title>The prognostic implication of basal-like (cycline E high/p27 low/p53+ glomeruloid-microvascular-proliferation +) phenotype of <italic>BRCA1</italic>-related breast cancer</article-title><source>Cancer Res</source><year>2004</year><volume>64</volume><fpage>830</fpage><lpage>835</lpage><pub-id pub-id-type="pmid">14871808</pub-id><pub-id pub-id-type="doi">10.1158/0008-5472.CAN-03-2970</pub-id></citation></ref><ref id="B29"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Omoto</surname><given-names>Y</given-names></name><name><surname>Inoue</surname><given-names>S</given-names></name><name><surname>Ogawa</surname><given-names>S</given-names></name><name><surname>Toyama</surname><given-names>T</given-names></name><name><surname>Yamashita</surname><given-names>H</given-names></name><name><surname>Muramatsu</surname><given-names>M</given-names></name><name><surname>Kobayashi</surname><given-names>S</given-names></name><name><surname>Iwase</surname><given-names>H</given-names></name></person-group><article-title>Clinical value of the wild-type estrogen receptor beta expression in breast cancer</article-title><source>Cancer Lett</source><year>2001</year><volume>163</volume><fpage>207</fpage><lpage>212</lpage><pub-id pub-id-type="pmid">11165756</pub-id><pub-id pub-id-type="doi">10.1016/S0304-3835(00)00680-7</pub-id></citation></ref><ref id="B30"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Hopp</surname><given-names>T</given-names></name><name><surname>Weiss</surname><given-names>H</given-names></name><name><surname>Parra</surname><given-names>I</given-names></name><name><surname>Cui</surname><given-names>Y</given-names></name><name><surname>Osborne</surname><given-names/></name><name><surname>Fuqua</surname><given-names>S</given-names></name></person-group><article-title>Low levels of estrogen receptor beta protein predict resistance to tamoxifen therapy in breast cancer</article-title><source>Clin Cancer Res</source><year>2004</year><volume>10</volume><fpage>7490</fpage><lpage>7499</lpage><pub-id pub-id-type="pmid">15569979</pub-id><pub-id pub-id-type="doi">10.1158/1078-0432.CCR-04-1114</pub-id></citation></ref><ref id="B31"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Esslimani-Sahla</surname><given-names>M</given-names></name><name><surname>Simony-Lafontaine</surname><given-names>J</given-names></name><name><surname>Kramar</surname><given-names>A</given-names></name><name><surname>Lavaill</surname><given-names>R</given-names></name><name><surname>Mollevi</surname><given-names>C</given-names></name><name><surname>Warner</surname><given-names>M</given-names></name><name><surname>Gustafsson</surname><given-names>J-A</given-names></name><name><surname>Rochefort</surname><given-names>H</given-names></name></person-group><article-title>Estrogen receptor beta (ERbeta) level but not its ERbetacx variant helps to predict tamoxifen resistance in breast cancer</article-title><source>Clin Cancer Res</source><year>2004</year><volume>10</volume><fpage>5769</fpage><lpage>5776</lpage><pub-id pub-id-type="pmid">15355905</pub-id><pub-id pub-id-type="doi">10.1158/1078-0432.CCR-04-0389</pub-id></citation></ref><ref id="B32"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>O'Neill</surname><given-names>P</given-names></name><name><surname>Davies</surname><given-names>M</given-names></name><name><surname>Shaaban</surname><given-names>A</given-names></name><name><surname>Innes</surname><given-names>H</given-names></name><name><surname>Torevell</surname><given-names>A</given-names></name><name><surname>Sibson</surname><given-names>D</given-names></name><name><surname>Foster</surname><given-names>C</given-names></name></person-group><article-title>Wild-type oestrogen receptor beta (ERbeta1) mRNA and protein expression in Tamoxifen-treated post-menopausal breast cancers</article-title><source>Br J Cancer</source><year>2004</year><volume>91</volume><fpage>1694</fpage><lpage>1702</lpage><pub-id pub-id-type="pmid">15477865</pub-id></citation></ref><ref id="B33"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Murphy</surname><given-names>LC</given-names></name><name><surname>Watson</surname><given-names>PH</given-names></name></person-group><article-title>Is oestrogen receptor-&#x003b2; predictor of endocrine therapy responsiveness in human breast cancer</article-title><source>Endocr Relat Cancer</source><year>2006</year><volume>13</volume><fpage>327</fpage><lpage>334</lpage><pub-id pub-id-type="pmid">16728566</pub-id><pub-id pub-id-type="doi">10.1677/erc.1.01141</pub-id></citation></ref><ref id="B34"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>de la Hoya</surname><given-names>M</given-names></name><name><surname>Osario</surname><given-names>A</given-names></name><name><surname>Godino</surname><given-names>J</given-names></name><name><surname>Sullerio</surname><given-names>S</given-names></name><name><surname>Tosar</surname><given-names>A</given-names></name><name><surname>Perez-Segura</surname><given-names>P</given-names></name><name><surname>Fernandez</surname><given-names>C</given-names></name><name><surname>Rodr&#x000ed;guez</surname><given-names>R</given-names></name><name><surname>D&#x000ed;az-Rubio</surname><given-names>E</given-names></name><name><surname>Ben&#x000ed;tez</surname><given-names>J</given-names></name><name><surname>Devilee</surname><given-names>P</given-names></name><name><surname>Cald&#x000e9;s</surname><given-names>T</given-names></name></person-group><article-title>Association between <italic>BRCA1 </italic>and BRCA2 mutations and cancer phenotype in Spanish breast/ovarian cancer families: implication for genetic testing</article-title><source>Int J Cancer</source><year>2002</year><volume>97</volume><fpage>466</fpage><lpage>471</lpage><pub-id pub-id-type="pmid">11802208</pub-id><pub-id pub-id-type="doi">10.1002/ijc.1627</pub-id></citation></ref><ref id="B35"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Adem</surname><given-names>C</given-names></name><name><surname>Reynolds</surname><given-names>C</given-names></name><name><surname>Soderberg</surname><given-names>CL</given-names></name><name><surname>Slezak</surname><given-names>JM</given-names></name><name><surname>McDonnell</surname><given-names>SK</given-names></name><name><surname>Sebo</surname><given-names>TJ</given-names></name><name><surname>Schaid</surname><given-names>DJ</given-names></name><name><surname>Myers</surname><given-names>JL</given-names></name><name><surname>Sellers</surname><given-names>TA</given-names></name><name><surname>Hartmann</surname><given-names>LC</given-names></name><name><surname>Jenkins</surname><given-names>RB</given-names></name></person-group><article-title>Pathologic characteristics of breast parenchyma in patients with hereditary breast carcinoma, including <italic>BRCA1 </italic>and BRCA2 mutation carriers</article-title><source>Cancer</source><year>2003</year><volume>97</volume><fpage>1</fpage><lpage>11</lpage><pub-id pub-id-type="pmid">12491499</pub-id><pub-id pub-id-type="doi">10.1002/cncr.11048</pub-id></citation></ref><ref id="B36"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Rosen</surname><given-names>EM</given-names></name><name><surname>Fan</surname><given-names>S</given-names></name><name><surname>Isaacs</surname><given-names>C</given-names></name></person-group><article-title><italic>BRCA1 </italic>in hormonal carcinogenesis: basic and clinical research</article-title><source>Endocr Relat Cancer</source><year>2005</year><volume>12</volume><fpage>533</fpage><lpage>548</lpage><pub-id pub-id-type="pmid">16172191</pub-id><pub-id pub-id-type="doi">10.1677/erc.1.00972</pub-id></citation></ref><ref id="B37"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Daidone</surname><given-names>MG</given-names></name><name><surname>Veneroni</surname><given-names>S</given-names></name><name><surname>Capelletti</surname><given-names>V</given-names></name><name><surname>Radice</surname><given-names>P</given-names></name><name><surname>Pierotti</surname><given-names>MA</given-names></name><name><surname>Younes</surname><given-names>M</given-names></name></person-group><article-title>Estrogen receptor-beta expression in hereditary breast cancer</article-title><source>J Clin Oncol</source><year>2002</year><volume>20</volume><fpage>3752</fpage><lpage>3753</lpage><pub-id pub-id-type="pmid">12202682</pub-id><pub-id pub-id-type="doi">10.1200/JCO.2002.99.116</pub-id></citation></ref><ref id="B38"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Gruvberger-Saal</surname><given-names>SK</given-names></name><name><surname>Bendahl</surname><given-names>PO</given-names></name><name><surname>Saal</surname><given-names>LH</given-names></name><name><surname>Laakso</surname><given-names>M</given-names></name><name><surname>Hegardt</surname><given-names>C</given-names></name><name><surname>Eden</surname><given-names>P</given-names></name><name><surname>Peterson</surname><given-names>C</given-names></name><name><surname>Malmstro</surname><given-names>P</given-names></name><name><surname>Isola</surname><given-names>J</given-names></name><name><surname>Borg</surname><given-names>A</given-names></name><name><surname>Ferno</surname><given-names>M</given-names></name></person-group><article-title>Estrogen receptor &#x003b2; expression is associated with tamoxifen response in ER&#x003b1;-negative breast carcinoma</article-title><source>Clin Cancer Res</source><year>2007</year><volume>13</volume><fpage>1987</fpage><lpage>1994</lpage><pub-id pub-id-type="pmid">17404078</pub-id><pub-id pub-id-type="doi">10.1158/1078-0432.CCR-06-1823</pub-id></citation></ref></ref-list></back></article> 